Multidrug -or Carbapenem-resistant Gram-negative Infections: Efficacy and Safety Assessment of Siderophore Cephalosporin Cefiderocol, Highlighting Infection-causative bacterial analysis in Japan -MUSASHI study-

Multidrug -or Carbapenem-resistant Gram-negative Infections: Efficacy and Safety Assessment of Siderophore Cephalosporin Cefiderocol, Highlighting Infection-causative bacterial analysis in Japan -MUSASHI study- - Multidrug -or Carbapenem-resistant Gram-negative Infections: Efficacy and Safety Assessment of Siderophore Cephalosporin Cefiderocol, Highlighting Infection-causative bacterial analysis in Japan -MUSASHI study-

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053214

Enrollment

100

Registered

2023-12-25

Start date

2023-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who participated in the post marketing survey of Cefidelocol Patients who have obtained written consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients who used cefidrocol for other indications than in the package insert Patients who have received Cefidelocol for less than 72 hours

Design outcomes

Primary

Measure	Time frame
Characteristics of patients treated with cefiderocol	—

Countries

Japan

Contacts

Public ContactIppei Morita

Shionogi & Co., Ltd. Medical Affairs Department

ippei.morita@shionogi.co.jp+81-6-6202-2161

Outcome results